Answer -
(a) Answer -
Basic earnings per share = $1.43
Calculation :
Preferred dividend = $1300000 * 5% = $65000
Basic earnings per share = (Net income - Preferred dividend) / Weighted average common shares outstanding
Basic earnings per share = ($1480000 - $65000) / 990000
Basic earnings per share = $1.4292
(b) Answer -
Diluted earnings per share = $1.31
Calculation :
Need to see convertible bonds and stock options fit the test of dilution.
So,
7% convertible bonds :
Interest on convertible bonds
= $5070000 * 7% - Income tax (20%)
= $354900 - Income tax (20%)
= $283920
Converted common shares
= ($5070000 / $1000) * $50
= $253500
7% convertible bonds = Interest on convertible bonds / Converted common shares
7% convertible bonds = $283920 / 253500
7% convertible bonds = $1.12
Since,
Basic earnings per share ($1.43) is greater than 7% convertible bonds ($1.12)
So, it can be said that the 7% convertible bonds are dilutive.
Stock options :
Since the average market price $20 per share is greater than option price $14 per share.
So, the stock options are dilutive.
Incremental shares = [(Market price - Option price) / Market price] * No. of options
Incremental shares = [($20 - $14) / $20] * 190000
Incremental shares = 57000
Potentially dilutive common shares = Converted common shares + Incremental shares
Potentially dilutive common shares = 253500 + 57000
Potentially dilutive common shares = 310500
Diluted earnings per share :
Diluted earnings per share = (Net income - Preferred dividend + Interest on convertible bonds) / (Average common shares + Potentially dilutive common shares)
Diluted earnings per share = ($1480000 - $65000 + $283920) / (990000 + 310500)
Diluted earnings per share = $1.3063
Question 6 --/1 View Policies Current Attempt in Progress Amy Dyken, controller at Teal Pharmaceutical Industries,...
--/1 Question 6 View Policies Current Attempt in Progress Amy Dyken, controller at Grouper Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Grouper's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Grouper Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 8% convertible bonds payable 10% bonds payable Total long-term debt $1,000,000 5,080,000 5,940,000...
Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Wildhorse’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Wildhorse Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11% $1,020,000 9% convertible bonds payable 5,020,000 11% bonds payable 6,120,000 Total long-term debt $12,160,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Wildhorse’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Wildhorse Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 9% convertible bonds payable 4,970,000 10% bonds payable 5,980,000 Total long-term debt $11,970,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sunland Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $990,000 5,040,000 6,080,000 $12,110,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Bridgeport Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Bridgeport’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Bridgeport Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $990,000 9% convertible bonds payable 5,040,000 10% bonds payable 6,080,000 Total long-term debt $12,110,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sunland Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $990,000 5,040,000 6,080,000 $12,110,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
16.2 #3 PLEASE SHOW ALL WORK Amy Dyken, controller at Swifty Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Swifty's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Swifty Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $1,010,000 5,090,000 6,060,000 $12,160,000 Shareholders' equity...
Amy Dyken, controller at Blossom Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Blossom’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Blossom Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Waterway Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Waterway’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Waterway Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sandhill’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sandhill Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,010,000 9% convertible bonds payable 5,030,000 10% bonds payable 5,990,000 Total long-term debt $12,030,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...